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Abstract
Aims/hypothesis TBC1 domain family, member 4 (TBC1D4;
also known as AS160) is a cellular signalling intermediate to
glucose transport regulated by insulin-dependent and
-independent mechanisms. Skeletal muscle insulin sensitivity
is increased after acute exercise by an unknown mechanism
that does not involve modulation at proximal insulin
signalling intermediates. We hypothesised that signalling
through TBC1D4 is involved in this effect of exercise as it is
a common signalling element for insulin and exercise.
Methods Insulin-regulated glucose metabolism was evalu-
ated in 12 healthy moderately trained young men 4 h after
one-legged exercise at basal and during a euglycaemic–
hyperinsulinaemic clamp. Vastus lateralis biopsies were
taken before and immediately after the clamp.
Results Insulin stimulation increased glucose uptake in
both legs, with greater effects (~80%, p<0.01) in the
previously exercised leg. TBC1D4 phosphorylation,
assessed using the phospho–AKT (protein kinase B)
substrate antibody and phospho- and site-specific anti-
bodies targeting six phosphorylation sites on TBC1D4,
increased at similar degrees to insulin stimulation in the
previously exercised and rested legs (p<0.01). However,
TBC1D4 phosphorylation on Ser-318, Ser-341, Ser-588
and Ser-751 was higher in the previously exercised leg,
both in the absence and in the presence of insulin (p<0.01;
Ser-588, p=0.09; observed power=0.39). 14–3–3 binding
capacity for TBC1D4 increased equally (p<0.01) in both
legs during insulin stimulation.
Conclusion/interpretation We provide evidence for site-
specific phosphorylation of TBC1D4 in human skeletal
muscle in response to physiological hyperinsulinaemia.
The data support the idea that TBC1D4 is a nexus for
insulin- and exercise-responsive signals that may mediate
increased insulin action after exercise.
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Introduction
Insulin sensitivity of skeletal muscle to stimulate glucose
uptake is markedly enhanced by a prior bout of exercise.
This effect is restricted to the previously contracted muscle,
rather than a consequence of changes in systemic factors
[1–8]. The enhanced insulin sensitivity that increases
glucose transport after acute exercise is associated with
recruitment of GLUT4 molecules to the plasma membrane
[9], but not with GLUT4 protein levels [10]. This effect
cannot be linked to increased signal transduction at the
insulin receptor or intermediates in proximal components of
the insulin signalling cascade involving IRS1, phosphoino-
sitide 3-kinase, AKT (protein kinase B) and glycogen
synthase kinase 3 [8, 10, 11].
TBC1 domain family, member 1 (TBC1D1) and member
4 (TBC1D4) are GTPase-activating proteins (GAP) and
direct targets of AKT [12, 13]. They are similar in size and
structure and run at approximately 150 to 160 kDa during
SDS-PAGE [14]. The GAP domain of both TBC1D1 and
TBC1D4 stimulates the GTPase activity of certain Rab
proteins, thereby inhibiting GLUT4 translocation to the
plasma membrane [13, 15, 16]. GTPase activity is thought
to be regulated by phosphorylation and both TBC1D1 and
TBC1D4 proteins contain multiple Ser/Thr residues that
can be phosphorylated by various kinases [13, 14, 17]. In
line with this, stimulation by aminoimidazole carboxamide
ribonucleotide, insulin and other growth factors, as well as
contraction of skeletal muscle, leads to phosphorylation of
TBC1D1 and/or TBC1D4 [18–22]. Beside phosphoryla-
tion, binding of 14–3–3 proteins to phosphorylated Thr-642
and/or Ser-341 of TBC1D4 [18, 23] is important for
glucose transport in 3T3-L1 adipocytes possibly via
regulation of the GAP domain [23].
Being multi-kinase substrates, TBC1D1 and TBC1D4
may be a point of convergence for insulin-dependent and
insulin-independent signalling pathways regulating glucose
transport in skeletal muscle. Indeed, both insulin- and
contraction-induced glucose uptake in skeletal muscle have
been shown to partly depend on TBC1D4 [24]. Conse-
quently, the intracellular signals emanating from the
contracting muscle during exercise may interact with the
insulin signalling pathway at the TBC1D1 or TBC1D4
level, thereby mediating enhanced glucose uptake in
previously exercised muscle [25]. Recent studies of rodent
and human skeletal muscle provide evidence for a role of
TBC1D4 in this respect [26–28], showing that TBC1D4
phosphorylation is increased in the hours following an
acute bout of exercise. However, although one study in rat
skeletal muscle has shown that prior exercise resulted in
enhanced basal and insulin-stimulated glucose uptake and
phosphorylation of TBC1D4 [26], no such evidence has
been generated in humans.
Phosphorylation of TBC1D1 and TBC1D4 has previ-
ously been evaluated using the phospho-AKT substrate
(PAS) antibody, which recognises phosphorylation sites on
AKT substrates lying in a (R/K)X(R/K)XXS*/T* sequence
motif. Thus, the interpretation of previous investigations
has been limited by the unselective nature of the PAS
antibody, which may recognise multiple phosphorylation
sites on TBC1D1 and TBC1D4 and mask potential site-
specific effects of exercise or insulin. It was recently
shown, however, that only Thr-642 on TBC1D4 and Thr-
596 on TBC1D1 are recognised by the PAS antibody [13,
18, 19], leaving several phosphorylation sites that are
potentially important for GAP activity unrecognised.
Furthermore, since TBC1D1 and TBC1D4 have similar
mobility on SDS-PAGE and since both proteins are
recognised by the PAS antibody, data from previous
investigations using this antibody should be interpreted
carefully [12, 21, 22, 29–35]. To circumvent these prob-
lems, we used phospho-specific antibodies against six
phosphorylation sites on TBC1D4. Our findings suggest
that site-specific TBC1D4 phosphorylation events may play
a role in mediating the beneficial effects of exercise on
skeletal muscle insulin action.
Methods
Participants The participants in this study were 12 young,
healthy men (age 24±1 years; weight 80±2.7 kg; height
188±2 cm; BMI 23±0.5 kg/m2; VO2peak 4.6±0.1 l/min),
who gave informed consent to participate. The study was
approved by the local Ethics Committee in the municipality
of Copenhagen (01-180/01) and performed in accordance
with the Helsinki declaration.
Experimental design Following 4 days of standardised diet
(65% of energy as carbohydrate, 20% as fat, 15% as
protein) the participants arrived at the laboratory in the
morning after an overnight fast. They ate a small,
carbohydrate-rich snack (5% daily energy intake) and then
performed 60 min of dynamic one-legged knee extensor
exercise (one kick/s) at ˜80% of peak workload of the knee
extensors [8]. During the 60 min of exercise, two 5 min
phases at 100% of peak workload were performed to ensure
activation of the majority of the vastus lateralis muscle. The
contralateral leg was kept at rest. After exercise, partic-
ipants rested in the supine position for 4 h. During the
resting period participants had Teflon catheters inserted
below the inguinal ligament in one femoral artery and both
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femoral veins and after 4 h of rest a 100 min euglycaemic–
hyperinsulinaemic clamp (9 nmol min−1 kg−1) was per-
formed as described previously [11]. Before and immedi-
ately after the clamp, biopsies from the vastus lateralis
muscle were taken under subcutaneous anaesthesia (~2–
3 ml xylocain [10 mg/ml lidocaine]; AstraZeneca, Söder-
tälje, Sweden) from the rested and exercised leg using
individual incisions. Specifically, to address mRNA iso-
form expression of TBC1D1 and TBC1D4, biopsies were
obtained from abdominal subcutaneous adipose tissue and
vastus lateralis muscle from eight participants in the rested,
non-stimulated state. All biopsies were quickly (<20 s)
frozen in liquid nitrogen and stored at −80°C.
Blood chemistry Glucose levels during the clamp were
measured in whole blood using an ABL 615 (Radiometer
Medical, Brønshøj, Denmark). Plasma insulin concentra-
tions were determined by RIA (DSL-1600; Diagnostic
Systems Laboratories, Webster, TX, USA).
Muscle and adipose tissue processing Muscle tissue was
freeze-dried, dissected free of visible fat and connective
tissue. Muscle and adipose tissue samples were homogenised
in ice-cold buffer (50 mmol/l HEPES, 150 mmol/l NaCl,
20 mmol/l Na4P2O7, 20 mmol/l β-glycerophosphate,
10 mmol/l NaF, 2 mmol/l Na3VO4, 2 mmol/l EDTA,
1% (vol./vol.) Nonidet P-40, 10% (vol./vol.) glycerol,
2 mmol/l phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin,
10 μg/ml aprotinin and 3 mmol/l benzamidine). Homoge-
nates were rotated end-over-end at 4°C for 1 h and subjected
to centrifugation (17,500×g, 4°C) for 20 min. Supernatant
fractions were collected and protein concentrations deter-
mined (Pierce, Rockford, IL, USA).
Glycogen Muscle glycogen was determined as glucosyl
units after acid hydrolysis. The analysis was performed by
fluorometry using freeze dried, dissected muscle specimens
as described [36].
Antibodies Phosphorylation of TBC1D1 and TBC1D4 was
measured using the PAS antibody (Cell Signaling Technol-
ogy, Boston, MA, USA) and phospho-specific antibodies
against TBC1D4 (Ser-318, Ser-341, Ser-588, Thr-642, Ser-
666 and Ser-751) as previously described [18]. Total
TBC1D4 protein was determined using an antibody specific
for human TBC1D4 (Abcam, Cambridge, UK). For 14–3–3
overlays, an antibody made against the C-terminal part of
TBC1D4 (KAKIGNKP) was applied in the immunoprecip-
itation step as described below. Total TBC1D1 antibody
was generated as described previously [19]. We have
previously determined that the TBC1D4 total antibody
from Abcam and the PAS antibody specifically detect
TBC1D4 in human skeletal muscle [37, 38]. Specificity of
the TBC1D4 phospho-specific antibodies and the TBC1D1
antibody has been confirmed using various cell lines [18,
19]. To further confirm specificity of the TBC1D4
phospho-specific antibodies, we performed immunodeple-
tion analyses using TBC1D1 and TBC1D4 antibodies and
muscle lysates from human skeletal muscle.
Immunoprecipitation of TBC1D4 and TBC1D1 TBC1D4
and TBC1D1 were immunoprecipitated from 300 μg of
protein from human skeletal muscle lysates using anti-
bodies bound to protein G agarose beads as previously
described [37]. Supernatant fractions from samples were
removed and immunocomplexes were subsequently washed
two times in PBS. The immunocomplexes were boiled in
Laemmli buffer and subjected to SDS-PAGE probing for
TBC1D4 and TBC1D1 protein and TBC1D4 phosphoryla-
tion using the antibodies described above.
SDS-PAGE and Western blot analyses Western blot analy-
ses were performed as previously described [37]. Mem-
branes probed with the phospho-specific antibodies for
TBC1D4 were stripped in a buffer containing 100 mmol/l
2-mercaptoethanol, 0.02 g/ml SDS and 62.5 mmol/l
Tris–HCl (pH 6.7), and re-probed with TBC1D4 antibody.
The signal from the phospho-specific antibodies was related
to total TBC1D4 in the sample.
Phosphorylation of Ser-666 Phosphorylation of Ser-666 on
TBC1D4 was measured by immunoprecipitating TBC1D4
protein from 150 μg of human skeletal muscle lysate. The
precipitant was subjected to SDS-PAGE as described above
and after visualisation membranes were stripped and
normalised to TBC1D4 protein as described above.
14–3–3 overlays We did 14–3–3 overlays as previously
described [39]. Briefly, endogenous TBC1D4 protein was
immunoprecipitated from 150 μg of human muscle lysates,
electrophoretically separated on gels (Nu-PAGE; Invitrogen,
Paisley, UK) and subsequently transferred on to nitrocellu-
lose membranes. Membranes were probed overnight at 4°C
with digoxigenin-labelled 14–3–3, followed by incubation
with a horseradish-peroxidase-conjugated anti-digoxigenin
antibody (Roche, Burgess Hill, UK). Immune complexes
were visualised and quantified (Odyssey Infrared Imaging
System; LI-COR Biosciences, Lincoln, NE, USA), and
normalised to TBC1D4 protein.
RNA isolation, reverse transcription, PCR and calculations
Procedures for isolation of RNA, reverse transcription,
determination of single-stranded cDNA content and PCR
have been described previously [40]. Primers and probes
used for the PCR reaction are presented in Table 1. All
TaqMan probes were 5′-6-carboxyfluorescein- and 3′-6-
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carboxy-N,N,N′,N′-tetramethylrhodamine-labelled. Individ-
ual standard curves were generated for each gene using a
serial dilution of a pooled skeletal muscle and a pooled
adipose tissue cDNA sample. Based on the slopes of the
standard curves, amplification efficiencies were similar for
the three sets of primers (91.6%, 88.7% and 91.2% for
TBC1D1, TBC1D4-short form and TBC1D4-long form,
respectively). Furthermore, the mRNA expression level of
the different genes was calculated by linear regression
(y=αx+β) using the gene-specific slopes (amplification
efficiencies) of the standard curves and a common β value.
The mRNA content of each gene was normalised to total
single-stranded cDNA in the specific sample.
Statistics All statistical analyses were conducted using
SPSS 16.0.1 (SPSS, Chicago, IL, USA). Levene’s test of
equality of variance was used to confirm that all groups had
equal variances. Two-way analyses of variance with
repeated measures for the factors ‘leg’ and ‘time’ were
used to test for main effects and interactions. A p value of
p<0.05 was considered statistically significant. Data are
expressed as means±SE.
Results
Skeletal muscle glycogen and whole-body glucose uptake At
4 h after exercise, skeletal muscle glycogen was lower in the
previously exercised leg (397±61 μmol/g) than in the rested
leg (618±48 μmol/g). Insulin levels reached a plateau of
680±5 pmol/l after 15 min of insulin stimulation. Thigh
glucose uptake was similar before the clamp commenced,
but was significantly higher (p<0.01) in the previously
exercised leg (6.7±0.6 mmol/kg [AUC]) than in the rested
leg during insulin stimulation (3.9±0.6 mmol/kg [AUC]),
indicating insulin action was enhanced in response to prior
exercise. This study is part of a larger investigation, which
is designed to assess metabolism and signalling events in
skeletal muscle in the post-exercise state. Additional data
from the experiment described here are presented in a
previous publication [11].
Phosphorylation of TBC1D4 after exercise Using the PAS
antibody and site-specific antibodies against TBC1D4, we
determined the phosphorylation status of TBC1D4 4 h after
termination of an acute exercise bout, just before and at the
end of a euglycaemic–hyperinsulinaemic clamp. TBC1D4
phosphorylation level determined using the PAS antibody
in response to insulin was substantially increased (p<0.01),
but to a similar level whether the legs had previously been
rested or exercised (Fig. 1a). This phosphorylation pattern
coincided with phosphorylation of Thr-642 and Ser-666
(Fig. 1b, c), which was also increased in response to insulin
(p<0.01 for main effect), but was unaltered between the
rested and exercised leg. Phosphorylation of all other sites
on TBC1D4 (Ser-318, Ser-341, Ser-588, Ser-751) measured
in these samples followed the same pattern: insulin induced
a marked phosphorylation in both the previously rested and
previously exercised legs (p<0.01 for main effect of
insulin). In addition, prior exercise was associated with
increased (p<0.01 for main effect) phosphorylation com-
pared with the previously rested leg, regardless of effects of
insulin treatment on these four sites (Fig. 1d–g). The main
effect of prior exercise in the Ser-588 data was only of
borderline significance (p=0.09; observed power=0.39)
(Fig. 1f).
14–3–3 binding capacity of TBC1D4 It has been shown
that 14–3–3 binds TBC1D4 in response to insulin treatment
of cultured cells. To evaluate whether 14–3–3 also binds to
TBC1D4 in skeletal muscle in response to insulin and
whether the binding capacity was altered by prior exercise,
we performed 14–3–3 overlay assays as previously de-
scribed [18]. The increase in binding capacity of 14–3–3 to
TBC1D4 in the previously exercised and rested leg in
response to insulin was similar. At 4 h after exercise,
binding capacity of 14–3–3 to TBC1D4 was not increased
in the non-stimulated muscle (Fig. 2).
Test of TBC1D1, TBC1D4 and phospho-TBC1D4 antibody
specificity To test the specificity of total TBC1D4 and
TBC1D1 antibodies, we immunodepleted TBC1D4 and
TBC1D1 from human skeletal muscle lysates and per-
formed Western blot analyses (Fig. 3a–c). Both antibodies
were able to completely remove all TBC1D4 or TBC1D1
protein from the supernatant fractions. However, a very
faint band detected by the TBC1D4 antibody was seen in
the TBC1D1 immunoprecipitate (Fig. 3a). Furthermore,
Table 1 Oligo sequences for primers and probes used for amplifying
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when TBC1D4 was immunoprecipitated and the pellet blotted
for TBC1D1, we detected a clear band running at 150 kDa
(Fig. 3b). Thus, TBC1D4 can be co-immunoprecipitated
with TBC1D1 and vice versa. By re-probing the membrane
shown in Fig. 3a with a mix of TBC1D1 and TBC1D4
antibodies, it became clear that TBC1D1 and TBC1D4 run
with different molecular mass (Fig. 3c). Thus, we conclude
that TBC1D1 and TBC1D4 antibodies do not cross-react
when used for direct blotting. In mouse skeletal muscle,
TBC1D1 is highly expressed and the signal obtained with
the PAS antibody associates primarily with TBC1D1 [14].
To evaluate this issue in human skeletal muscle, we
performed split blots by cutting the membrane through one
lane and blotting for TBC1D4 and/or TBC1D1 and/or PAS
(Fig. 3d). Clearly, the signal obtained with the PAS antibody
followed TBC1D4 and not TBC1D1 in human skeletal
muscle. These data are consistent with our observations that
immunoprecipitation of TBC1D4 completely depletes the
PAS signal from human skeletal muscle obtained in the non-
























































































































































































Fig. 1 TBC1D4 phosphoryla-
tion in the post-exercise state.
TBC1D4 phosphorylation was
evaluated in vastus lateralis
muscle samples obtained in the
basal state 4 h after termination
of a one-legged knee extensor
exercise bout (white bars) and at
the end of a euglycaemic–
hyperinsulinaemic clamp (black
bars) using the PAS antibody
and phospho-specific antibodies
targeting six of the known
phosphorylation sites on
TBC1D4. Values, in arbitrary
units (AU), are for (a) PAS, (b)
Thr-642, (c) Ser-666, (d) Ser-
318, (e) Ser-341, (f) Ser-588 and
(g) Ser-751. **p<0.01 for insu-
lin effect, n=12; ††p<0.01 for
prior exercise effect, n=12;
(†)p=0.09 borderline signifi-
cance, observed power=0.39,
n=12. h Representative blots
using TBC1D4 phospho-
specific antibodies. All antibod-
ies gave a single band running at
160 kDa. Ser-666 was measured
after immunoprecipitation of
TBC1D4; all other blots were
direct blots performed using
vastus lateralis muscle lysates
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(Fig. 3, [38]) and following exercise [37]. Thus, under
various conditions detectable PAS signal originated from
TBC1D4 in human skeletal muscle. Finally, to show that
the TBC1D4 phospho-specific antibodies detect only
TBC1D4 and not TBC1D1 in human skeletal muscle, we
immunoprecipitated TBC1D4 and incubated with different
phospho-TBC1D4 antibodies (Fig. 3e). All TBC1D4
phospho-antibodies detected a single band running at the
same molecular mass or slightly higher than the lysate
sample. Furthermore, no bands are detected in the superna-
tant fractions. Thus, based on the results presented in Fig. 3,
together with previously published data [18], we conclude
that the phospho-antibodies specifically detect TBC1D4 in
human skeletal muscle.
mRNA expression of TBC1D1 and TBC1D4 isoforms in
human vastus lateralis muscle and subcutaneous adipose
tissue Transcripts from two splice variants of mouse
TBC1D4 and TBC1D1 exist in the databases [13]. Further-
more, it has been found that skeletal muscle and white
adipose tissue from mice differentially express the different
splice variants [14]. It is not known whether these differ-
ences are also present in human skeletal muscle and
subcutaneous abdominal adipose tissue. From the transcript
sequences available, specific primers and probes were
generated directed against the short and long splice variants
of TBC1D4. Additionally and since only the short splice
variant of TBC1D1 is available in the databases, one set of
primers that amplify both the short and long variants of
TBC1D1 was generated. Our results showed that subcuta-
neous adipose tissue from humans expressed TBC1D1
mRNA and only the short version of TBC1D4, and levels
of TBC1D1 mRNA were approximately threefold greater








































Fig. 2 Binding capacity of 14–3–3 to TBC1D4 increased with insulin
as shown in (a). Following immunoprecipitation of TBC1D4, 14–3–3
binding capacity to TBC1D4 was evaluated by far-western overlay (b)
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Fig. 3 Verification of antibodies specificity. a TBC1D1 and TBC1D4
were immunoprecipitated from a human vastus lateralis muscle
sample and the immunoprecipitates (IP) (150 μg) loaded together
with the pre-IPs (lysate cleared with beads; 30 μg) and the post-IPs
(supernatant fraction; 30 μg). Following SDS-PAGE proteins were
transferred to PVDF membranes, which were then probed with
TBC1D4 antibody. b Same samples as above (a), but the membranes
were incubated with TBC1D1 antibody. c Membranes (a) were re-
incubated with a mixture of TBC1D1 and TBC1D4 antibodies and
developed to show the separation between TBC1D1 and TBC1D4. d
Western blot analyses were performed using an insulin-stimulated
human vastus lateralis muscle sample loaded in three wells. The
membrane was cut through the middle lane. The two membranes were
incubated with different antibodies as indicated. The different pieces
of membrane were put back together and developed. TBC1D1 and
TBC1D4 ran at different molecular masses, whereas the signal from
the PAS antibody aligned with TBC1D4, but not with TBC1D1. e
TBC1D4 was immunoprecipitated from the same sample used above
(d), and pre-IP (60 μg), post-IP (60 μg) and IP (120 μg) were
subjected to SDS-PAGE and transferred to PVDF membranes. These
were then incubated with antibodies as indicated. All bands in the IP
lane ran with the same, or slightly higher, molecular mass as the pre-
IP sample. IB, immunoblot
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expressed very small amounts of TBC1D4-short mRNA,
which could have been contamination from fat cells lying
between the muscle fibres. Moreover, TBC1D4-long and
TBC1D1 mRNA were approximately equally abundant in
human skeletal muscle. Using an antibody that detects both
splice variants of TBC1D4, we confirmed that TBC1D4-
short and TBC1D4-long mRNA are exclusively associated
with subcutaneous adipose tissue and skeletal muscle,
respectively (Fig. 4b). Within the amount of protein loaded
on the gel, we detected only a single band in each sample
running with the molecular mass corresponding to
TBC1D4-short and TBC1D4-long. Thus, these data con-
firm our mRNA data and are in agreement with data
obtained from mouse tissues [13, 14].
Discussion
We investigated whether acute exercise influences basal
and insulin-stimulated TBC1D4 phosphorylation in skeletal
muscle 4 h after an acute bout of exercise. We used
phospho-specific antibodies directed against six phosphor-
ylation sites on TBC1D4 to determine whether TBC1D4
was phosphorylated in the post-exercise state when insulin
action was increased in the previously exercised leg. We
show that TBC1D4 phosphorylation is increased in re-
sponse to physiological insulin stimulation on all of the six
sites investigated. Moreover, phosphorylation of Ser-318,
Ser-341, Ser-588 and Ser-751 was increased by prior
exercise, both before and immediately after insulin stimu-
lation. The differential phosphorylation of TBC1D4 is a
product of TBC1D4 kinases and phosphatases regulated
during and after exercise. Thus, it is likely that exercise
directly induces TBC1D4 phosphorylation on Ser-318, Ser-
341, Ser-588 and Ser-751. However, we cannot rule out the
possibility that Thr-642 and Ser-666 are also phosphorylat-
ed during exercise, but due to faster time-courses for
dephosphorylation no changes are present at 4 h after
exercise. Regardless of this, TBC1D4 phosphorylation was
maintained on specific sites in the hours after exercise, so
when insulin is present, translocation and fusion of GLUT4
molecules to the plasma membrane may be potentiated in
the exercised muscle. Therefore, TBC1D4 may be a ‘point of
convergence’ between insulin- and exercise-mediated signal-
ling pathways [25, 41]. Activation of AMP-activated protein
kinase (AMPK) in exercising human skeletal muscle is
associated with PAS-phosphorylation of TBC1D4 [37], and
in rodents, AMPK is involved in the phosphorylation of
TBC1D1 and/or TBC1D4 during contraction [21, 22]. So
although various regulators may be involved, it is tempting
to speculate that AMPK is one kinase involved in the
observed regulation of TBC1D4.
TBC1D4 regulation in human skeletal muscle has primar-
ily been assessed using the PAS antibody, which recognises
phosphorylated Ser/Thr residues in a (R/K)X(R/K)XXS*/T*
motif sequence. Although most of the known TBC1D4
phosphorylation sites have this lead-up sequence, antibody
recognition cannot be guaranteed. In fact, data indicate that
Thr-642 may be the primary phosphorylation site recog-
nised by the PAS antibody [18]. Interestingly, of all the
phosphorylation sites in the perfect consensus sequence
for detection by the PAS antibody (Thr-642, Ser-318,
Ser-341, Ser-588 and Ser-751,) only Thr-642 showed a
pattern of phosphorylation similar to that detected using
the PAS antibody.
Little is known about TBC1D4 regulation in skeletal
muscle in the post-exercise state. In healthy humans, TBC1D1
and/or TBC1D4 phosphorylation assessed using the PAS
antibody was enhanced after endurance type exercise,
whereas the response to insulin was not [27]. Likewise, in
the hours after a bout of resistance exercise, PAS phosphor-
ylation was also elevated in human skeletal muscle [28]. In
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Fig. 4 a mRNA expression of human TBC1D1 and TBC1D4 splice
variants in skeletal muscle and subcutaneous adipose tissue. Relative
amounts of the different gene products were calculated and compared.
Adipose tissue (white bars) exclusively expressed the short (-S)
version of TBC1D4 and TBC1D1. Expression of TBC1D1 was
approximately threefold higher than that of TBC1D4 in adipose tissue.
Skeletal muscle (black bars) expressed equal amounts of TBC1D4-
long (-L) and TBC1D1, but only very small amounts of TBC1D4-S,
which may be contamination from inter-myocellular fat cells. b
TBC1D4 Western blot showing that human skeletal muscle (M) and
subcutaneous adipose tissue (A) differentially produce TBC1D4-L and
TBC1D4-S splice variant proteins. **p<0.01 vs TBC1D4-S within
tissue, (n=8); ††p<0.01 for within gene, n=8. IB, immunoblot
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unchanged, TBC1D4 phosphorylation at specific sites (Ser-
318, Ser-341 and Ser-751) is enhanced both in the basal and
insulin-stimulated state 4 h after exercise. Time, mode and
intensity of the exercise bout, and the following resting
period may explain the differences between this study and
previously published data [27, 28]. A likely scenario is that
exercise as such increases PAS phosphorylation [31, 37] and
when the exercise is terminated, PAS phosphorylation
gradually decreases towards baseline. Thus, in the present
study, we cannot exclude the possibility that basal PAS
phosphorylation was still increased ~3 h into recovery but
reached baseline at 4 h. Moreover, the enhanced basal and
insulin-stimulated PAS phosphorylation observed in rat
skeletal muscle after exercise [26] was not observed here in
human skeletal muscle. While all available data point to a
role for TBC1D4 in the post-exercise situation, regulation of
TBC1D4 may differ across exercise regimes and animal
species.
In this study we also investigated the ability of 14–3–3
proteins to interact with TBC1D4. We provide evidence
that 14–3–3 binds to TBC1D4 in response to insulin,
confirming previous findings [27]. Cell studies suggest that
14–3–3 binds to TBC1D4 Ser-341 and Thr-642 upon
phosphorylation [18, 23]. It is possible that other sites on
TBC1D4 bind 14–3–3 in vivo, although this may be
difficult to prove due to weak association between TBC1D4
and 14–3–3 [18]. Nevertheless, as 14–3–3 binding was not
elevated by prior exercise (Fig. 2a), this binding may not be
important in the enhanced insulin action observed. Also, the
present data would suggest that Ser-318, Ser-341 and Ser-
751 do not contribute to 14–3–3 binding, since the phosphor-
ylation pattern and 14–3–3 binding do not coincide. Statistical
analyses revealed that the interaction effect in the 14–3–3 data
was of borderline significance (p=0.08; observed power=
0.54). Thus, we may have missed a real effect due to lack of
statistical power. However, if prior exercise does decrease
the ability of insulin to promote 14–3–3 binding, this would
be counterintuitive given previous data suggesting 14–3–3
binding promotes inhibition of TBC1D4 and thus increases
GLUT4 translocation [23].
TBC1D4 shares similar features to TBC1D1 and is also
present in mouse skeletal muscle [13, 14, 42]. The GAP
domain of the two proteins is highly similar and both
proteins are thought to be regulated by phosphorylation.
Thus, TBC1D4 and TBC1D1 may play redundant roles in
tissues in which they are present. There is now strong
evidence to support a role for TBC1D1 and TBC1D4 in
regulating glucose transport in skeletal muscle and adipo-
cytes [13, 17, 24, 43]. Thus, TBC1D1may also be important
for the increased insulin sensitivity in skeletal muscle after
exercise. The sequence around Thr-642 in TBC1D4 is
similar to the sequence around Thr-596 in TBC1D1, and
data from 3T3-L1 adipocytes and HEK-293 cells indicate
that Thr-596 is the main phosphorylation site detected by the
PAS antibody [13, 19]. TBC1D1 is abundant in mouse
skeletal muscle [14, 42], and TBC1D1 and TBC1D4
migrate at almost the same molecular mass during SDS-
PAGE [14]. In addition, phosphorylation measured by the
PAS antibody in mouse skeletal muscle containing a high
proportion of type II glycolytic fibres actually originates
from TBC1D1 [14]. This raises the question of whether
both TBC1D4 and TBC1D1 phosphorylation were deter-
mined in our previous studies in human skeletal muscle,
where the PAS antibody was used for immunoblot experi-
ments [37, 38, 44]. In fact, TBC1D1 is expressed in human
skeletal muscle at the mRNA level (Fig. 4) and at the
protein level (Fig. 3). Still, we verified our previous finding
showing PAS phosphorylation in response to insulin can be
completely accounted for in TBC1D4 immunoprecipitates
[37, 38]. Also, TBC1D1 and TBC1D4 migrated with
visibly different molecular mass (Fig. 3d) and the de-
tectable PAS signal was exclusively associated with
TBC1D4 and not with TBC1D1 in human skeletal muscle.
We cannot easily explain the observed differences between
human and mouse skeletal muscle regarding the different
levels of TBC1D1 and TBC1D4, and the level of the PAS
signal associated with these proteins. However, mouse
skeletal muscles are generally highly glycolytic [45]
compared with human vastus lateralis muscle [46], so
levels of TBC1D1 and TBC1D4 are likely to be associated
with the myosin heavy-chain isoform expression profile.
We showed in Fig. 3a, b that TBC1D1 was partially
pulled down in the TBC1D4 immunoprecipitate and vice-
versa. We cannot exclude the possibility that the TBC1D1
and TBC1D4 antibodies detect TBC1D1 and TBC1D4 in
their native, folded conformation. However, it is more
likely that TBC1D1 and TBC1D4 dimerise, so when
TBC1D4 is immunoprecipitated TBC1D1 co-precipitates
[19]. Although the quantitative level of these proteins is
unknown, the present finding indicates that the fraction of
total TBC1D1 associated with TBC1D4 is larger than the
fraction of total TBC1D4 that associates with TBC1D1. To
further explore the relation between TBC1D1 and
TBC1D4, we measured the mRNA content of TBC1D1
and TBC1D4 splice variants, both in human skeletal muscle
and subcutaneous adipose tissue. While skeletal muscle
primarily expressed TBC1D4-long and TBC1D1 in equal
amounts, adipose tissue contained more TBC1D1 than
TBC1D4-short. This mRNA expression profile is in
contrast to protein content previously reported in mouse
skeletal muscle and white adipose tissue [14, 42]. Thus,
further investigation is necessary to determine whether our
mRNA data translate directly into protein content in human
skeletal muscle and white adipose tissue.
In summary, we have used phospho-specific antibodies
to provide direct evidence for insulin-induced phosphor-
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ylation of TBC1D4. Moreover, phosphorylation of Ser-318,
Ser-341, Ser-588 (p=0.09; observed power=0.39) and Ser-
751 was increased in the basal, as well as insulin-stimulated
state 4 h after acute exercise. This finding constitutes an
advance in our understanding of the molecular mechanisms
underlying enhanced skeletal muscle insulin action after
exercise. Furthermore, we provide new insight into the
potential mechanism by which insulin- and exercise-
mediated signalling pathways converge on TBC1D4 to
increase glucose uptake in skeletal muscle.
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